Table 2.

Body Composition Data at Baseline and 4-Mo Follow-up by Randomization Group Note that all groups were assigned to 4-months of weight loss treatment

	No RT + No Pioglitazone			No RT + Pioglitazone			RT + No Pioglitazone			RT + Pioglitazone
	BL	FU	Absolute Change	BL	FU	Absolute Change	BL	FU	Absolute Change	BL	FU	Absolute Change
Women
n	10	9		10	9		10	9		10	10
Body mass (kg)	91.02±13.49	85.65±15.43	−5.77±2.48	90.07±13.70	85.33±13.20	−5.10±3.32	82.97±12.99	76.06±12.42	−6.98±4.24	93.14±17.65	87.90±18.10	−5.24±2.42
Fat mass (kg)	39.06±7.16	35.38±8.44	−3.71±1.95	39.72±8.09	37.28±8.33	−2.96±2.80	34.99±8.38	30.40±8.75	−5.04±2.53	41.45±10.15	38.07±10.96	−3.38±1.89
LBM (kg)	49.75±7.51	48.03 ± 7.93	−2.08±1.29	48.22 ± 6.43	45.95 ± 5.88	−2.14±1.89	45.93 ± 6.38	43.69 ± 5.22	−1.94±2.05	49.45 ± 7.79	47.61 ± 7.25	−1.84±1.55
aLBM (kg)	20.84±3.92	19.89±4.15	−1.12±1.00	20.58±3.30	19.40±2.98	−1.09±1.19	19.09±3.42	18.23±2.72	−0.86±1.13	21.03±3.05	20.00±2.98	−1.04±0.87
Men
N	12	11		12	10		12	11		12	12
Body mass (kg)	98.80 ± 13.71	91.80 ± 13.51	−6.90±4.50	99.22 ± 9.69	90.37 ± 13.54	−8.11±5.12	106.48 ± 14.87	100.28 ± 13.06	−5.41±4.09	106.81 ± 13.84	100.30 ± 12.45	−6.51±4.78
Fat mass (kg)	29.57±5.91	25.37 ± 6.49	−3.90±2.56	29.35 ± 6.45	24.05 ± 8.35	−5.48±3.18	36.43 ± 11.46	31.97 ± 10.56	−3.60±2.40	34.78 ± 10.08	29.70 ± 9.93	−5.08±3.72
LBM (kg)	66.48±8.87	63.68±8.15	−3.01±2.23	67.01±5.35	63.46±5.90	−2.62±2.31	67.21±5.80	65.42±5.20	−1.84±2.10	68.91±7.15	67.46±5.63	−1.45±2.49
aLBM (kg)	29.05 ± 4.29	27.55 ± 4.21	−1.59±0.98	29.42 ± 2.35	27.75 ± 2.63	−1.27±1.12	29.71 ± 3.42	28.74 ± 3.06	−0.88±1.15	30.41 ± 3.74	29.52 ± 3.14	−0.89±1.13

Notes. All groups were assigned to 4 months of weight loss treatment. Data are mean ± SD. RT, resistance training; BL, baseline; FU, 4-month follow-up; LBM, lean body mass; aLBM, appendicular lean body mass.